[A25-59] Repotrectinib (NSCLC) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2025
Project no.:
A25-59
Commission:
Commission awarded on 30.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-59
| Project no. | Title | Status |
|---|---|---|
| A25-58 | Repotrectinib (solid tumours with neurotrophic tyrosine receptor kinase [NTRK] gene fusion) – Benefit assessment according to §35a Social Code Book V | Commission completed |